Assessment of a subgroup of a cohort study revealed that many patients undergoing tamoxifen therapy for early-stage breast cancer do not adhere to their prescribed treatment, even though they claim adherence on patient surveys.
Tamoxifen or exemestane plus ovarian suppression more effectively increases survival than tamoxifen alone for premenopausal women with breast cancer.
No additional risk of colorectal cancer was noted among women treated with aromatase inhibitors (AIs) following a median follow-up of 2.4 and 2.9 years.
Lifelong soy consumption improves tamoxifen response in women with breast cancer; however, adding soy to diet after initiating tamoxifen therapy may not provide the same benefits.
For women receiving tamoxifen in the adjuvant setting for early stage breast cancer or as a preventive for high risk of breast cancer, the risk of developing endometrial pathology in those with negative uterine examination findings prior to treatment is very low.
Combining 2 existing chemotherapy drugs, a DNMT1 inhibitor and a histone deacetylase inhibitor, reduced the numbers of cancer stem cells and improved survival in a mouse model.
New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.
[OncoTargets and Therapy] This article examines possible survival benefits of ovarian function suppression (OFS) when combined with adjuvant tamoxifen treatment for breast cancer in premenopausal women.
The worse outcomes for African American women with estrogen-receptor positive (ER+) breast cancer, when compared with European American patients, appears to be related to a reduced cellular sensitivity to tamoxifen.
Researchers examined the benefits and risks associated with taking drug tamoxifen for breast cancer prevention.
